Synthesis and biological evaluation of 2-(3′,4′,5′-trimethoxybenzoyl)-3-N,N-dimethylamino benzo[b]furan derivatives as inhibitors of tubulin polymerization

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 18, 2008, Pages 8419-8426

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Sarkar, Taradas ^b   Carrion, Maria Dora ^a   Cruz Lopez, Olga ^a   Lopez Cara, Carlota ^a   Tolomeo, Manlio ^c   Grimaudo, Stefania ^d   Di Cristina, Antonietta ^d   Pipitone, Maria Rosaria ^d   Balzarini, Jan ^e   Gambari, Roberto ^a   Ilaria, Lampronti ^a   Saletti, Roberto ^f   Brancale, Andrea ^f   Hamel, Ernest ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b Developmental Therapeutics Program   (United States)

^c Servizio AIDS   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Bioisosteric replacement; Colchicine binding site; Combretastatin A 4; Microtubules; Tubulin polymerization

Indexed keywords

2 (3',4',5' TRIMETHOXYBENZOYL) 3 N,N DIMETHYLAMINOBENZO[B]FURAN DERIVATIVE; 2 (3,4,5 TRIMETHOXYBENZOYL) 3 DIMETHYLAMINO 6 METHOXYBENZO[B]FURAN; BENZOFURAN DERIVATIVE; COLCHICINE; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; IC 50; LEUKEMIA L 1210; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; REACTION ANALYSIS;

ANIMALS; ANTIMITOTIC AGENTS; BENZOFURANS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INHIBITORY CONCENTRATION 50; MICE; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS; TUMOR CELLS, CULTURED;

EID: 51649099415     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.08.029     Document Type: Article

References (29)

1. Kiselyov A., and Bulakin K.V. Anti-Cancer Agents Med. Chem. 7 (2007) 189
2. Nagle A., Hur W., and Gray N.S. Curr. Drug Targets 7 (2006) 305
3. Pasquier E., Andrè N., and Braguer D. Curr. Cancer Drug Targets 7 (2007) 566
4. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., and Garcia-Kendall D. Experentia 45 (1989) 209
5. Chaplin D.J., Horsman M.R., and Siemann D.W. Curr. Opin. Invest. Drugs 7 (2006) 522
6. Lin C.M., Ho H.H., Pettit G.R., and Hamel E. Biochemistry 28 (1989) 6984
7. Tron G.C., Pirali T., Sorba G., Pagliai F., Busacca S., and Genazzani A.A. J. Med. Chem. 49 (2006) 3033
8. Romagnoli R., Baraldi P.G., Carrion M.D., Lopez Cara C., Preti D., Fruttarolo F., Pavani M.G., Tabrizi M.A., Tolomeo M., Grimaudo S., Di Antonella C., Balzarini J., Hadfield J.A., Brancale A., and Hamel E. J. Med. Chem. 50 (2007) 2273
9. Romagnoli R., Baraldi P.G., Sarkar T., Carrion M.D., Lopez-Cara C., Cruz-Lopez O., Preti D., Tabrizi M.A., Tolomeo M., Grimaudo S., Di Cristina A., Zonta N., Balzarini J., Brancale A., Hsieh H.P., and Hamel E. J. Med. Chem. 51 (2008) 1464
10. Baker B., and Devan B.P. J. Am. Chem. Soc. 111 (1989) 2700
11. Jiang J.-D., Roboz J., Weisz I., Deng L., Ma L., Holland J.F., and Bekesi J.G. Anti-Cancer Drug Des. 13 (1998) 735
12. Song D.-Q., Wang Y., Wu L.-Z., Yang P., Wang Y.-M., Gao L.-M., Li Y., Qu J.-R., Wang Y.-H., Li Y.-H., Du N.N., Han Y.-X., Zhang Z.-P., and Jiang J.D. J. Med. Chem. 51 (2008) 3094
13. Luduena R.F., and Roach M.C. Pharmacol. Ther. 49 (1991) 133
14. Hargreaves A.J., Glazier A.P., Flaskos J., Mullins F.H., and McLean W.G. Biochem. Pharmacol. 47 (1994) 1137
15. Flynn B.L., Hamel E., and Jung M.K. J. Med. Chem. 45 (2002) 2670
16. For the synthesis of 8b-e, see the procedure reported in the article:. Karmarkar S.N., Kelkar S.L., and Wadia M.S. Synthesis (1985) 510
17. For the characterization of the 2-hydroxy-6-methoxybenzonitrile (8b) see:. Hwu J.R., Wong F.F., Huang J.-J., and Tsay S.-C. J. Org. Chem. 62 (1997) 4097
18. For the characterization of the 2-hydroxy-5-methoxybenzonitrile (8c) and 2-hydroxy-4-methoxybenzonitrile (8d) see:. Adachi M., and Sugasawa T. Synth. Commun. 20 (1990) 71
19. For the characterization of the 2-hydroxy-3-methoxybenzonitrile (8e) see:. Dewan S.K., Singh R., and Kumar A. Synth. Commun. 34 (2004) 2025
20. Hamel E. Cell Biochem. Biophys. 38 (2003) 1
21. Verdier-Pinard P., Lai J.-Y., Yoo H.-D., Yu J., Marquez B., Nagle D.G., Nambu M., White J.D., Falck J.R., Gerwick W.H., Day B.W., and Hamel E. Mol. Pharmacol. 53 (1998) 62
22. Korb O., Stützle T., and Exner T.E. Swarm Intell. 1 (2007) 115
23. Tripos SYBYL 7.3; Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144, USA. http://www.tripos.com.
24. Molecular Operating Environment (MOE 2006.08). Chemical Computing Group, Inc., Montreal, Que., Canada. http://www.chemcomp.com.
25. De Martino G., Edler M.C., La Regina G., Coluccia A., Barbera M.C., Barrow D., Nicholson R.I., Chiosis G., Brancale A., Hamel E., Artico M., and Silvestri R. J. Med. Chem. 49 (2006) 947
26. Ravelli R.B.G., Gigant B., Curmi P.A., Jourdain I., Lachkar S., Sobel A., and Knossow M. Nature 428 (2004) 198
27. Hamel E., and Lin C.M. Biochemistry 23 (1984) 4173
28. Zodiac 0.3.5b. http://www.zeden.org.
29. Code 'fragment_rmsd.svl' obtained from SLV Exchange website http://svl.chemcomp.com. Chemical Computing Group, Inc., Montreal, Canada.